Zobrazeno 1 - 10
of 81
pro vyhledávání: '"Daniel D Mikol"'
Autor:
Stewart J Tepper, Messoud Ashina, Uwe Reuter, Yngve Hallström, Gregor Broessner, Jo H Bonner, Hernan Picard, Sunfa Cheng, Denise E Chou, Feng Zhang, Jan Klatt, Daniel D Mikol
Publikováno v:
The Journal of Headache and Pain, Vol 22, Iss 1, Pp 1-14 (2021)
Abstract Background In patients with migraine, overuse of acute medication, including migraine-specific medication (MSM) such as triptans and ergots, can lead to adverse health outcomes, including development of medication overuse headache. Here, we
Externí odkaz:
https://doaj.org/article/f54ae6be4c9d4082adbb8b624f052db3
Publikováno v:
Alzheimer's & Dementia. 18
Autor:
Shihua Wen, Surat Tanprawate, Nadia Tenenbaum, Naji Riachi, Peggy Hours-Zesiger, Shuu Jiun Wang, Debashish Chowdhury, Mei-Ling Sharon Tai, Artemio Roxas, Tai Tran Ngoc, Yi Jing Zhao, Subhayan Mondal, Byung-Kun Kim, Bibiana Saravia, Daniel D. Mikol, Shaloo Pandhi
Publikováno v:
Cephalalgia
Objective EMPOwER, a double-blind, randomised, phase 3 study, evaluated the efficacy and safety of erenumab in adults with episodic migraine from Asia, the Middle East, and Latin America. Methods Randomised patients (N = 900) received monthly subcuta
Autor:
Daniel D. Mikol, Koichi Hirata, Sunfa Cheng, Fei Xue, Yotaro Numachi, Yoshihisa Tatsuoka, Takao Takeshima, Fumihiko Sakai, Cheng Peng
Publikováno v:
Headache
Objective To assess long‐term (up to 2 years) efficacy, tolerability, and safety of erenumab for the prevention of episodic migraine (EM) in Japanese patients. Background Previously published results from the double‐blind treatment phase (DBTP) o
Autor:
Feng Zhang, Peter J. Goadsby, Stephen D. Silberstein, Gabriel Paiva da Silva Lima, David W. Dodick, Messoud Ashina, Uwe Reuter, Daniel D. Mikol, Sunfa Cheng, Fei Xue
Publikováno v:
European Journal of Neurology
Ashina, M, Goadsby, P J, Reuter, U, Silberstein, S, Dodick, D W, Xue, F, Zhang, F, Paiva Da Silva Lima, G, Cheng, S & Mikol, D D 2021, ' Long-term efficacy and safety of erenumab in migraine prevention: Results from a 5-year, open-label treatment phase of a randomized clinical trial ', European Journal of Neurology, vol. 28, no. 5, pp. 1716-1725 . https://doi.org/10.1111/ene.14715
Ashina, M, Goadsby, P J, Reuter, U, Silberstein, S, Dodick, D W, Xue, F, Zhang, F, Paiva Da Silva Lima, G, Cheng, S & Mikol, D D 2021, ' Long-term efficacy and safety of erenumab in migraine prevention: Results from a 5-year, open-label treatment phase of a randomized clinical trial ', European Journal of Neurology, vol. 28, no. 5, pp. 1716-1725 . https://doi.org/10.1111/ene.14715
Background and purpose Although erenumab has demonstrated significant reduction in migraine frequency and improved quality of life in studies lasting 3 to 12 months, little is known about long‐term therapy. Methods This study was an open‐label, 5
Autor:
Jo H. Bonner, Jan Klatt, Messoud Ashina, Lifen Zhou, David Doležil, Hernan Picard, Daniel D. Mikol
Publikováno v:
Ashina, M, Doležil, D, Bonner, J H, Zhou, L, Klatt, J, Picard, H & Mikol, D D 2021, ' A phase 2, randomized, double-blind, placebo-controlled trial of AMG 301, a pituitary adenylate cyclase-activating polypeptide PAC1 receptor monoclonal antibody for migraine prevention ', Cephalalgia, vol. 41, no. 1, pp. 33-44 . https://doi.org/10.1177/0333102420970889
Cephalalgia
Cephalalgia
Objective To assess the safety and efficacy of AMG 301, an inhibitor of the pituitary adenylate cyclase-activating polypeptide (PACAP)-1 (PAC1) receptor, for prevention of migraine. Methods In a double-blind trial, patients were randomized 4:3:3 to p
Autor:
Messoud Ashina, Stewart J. Tepper, Jan Lewis Brandes, Uwe Reuter, Guy P. Boudreau, Mark Weatherall, Andreas R. Gantenbein, David Doležil, Jan Klatt, Andrea Wang, Ananda Krishna Karanam, Sunfa Cheng, Daniel D. Mikol
Publikováno v:
Ashina, M, Tepper, S J, Brandes, J L, Reuter, U, Boudreau, G P, Weatherall, M, Gantenbein, A R, Doležil, D, Klatt, J, Wang, A, Karanam, A K, Cheng, S & Mikol, DD 2022, ' Long-term efficacy and safety of erenumab in patients with chronic migraine in whom prior preventive treatments had failed : A subgroup analysis ', Headache, vol. 62, no. 5, pp. 624-633 . https://doi.org/10.1111/head.14313
Objective: To assess the long-term efficacy and safety of erenumab in the subgroup of patients with chronic migraine (CM) in whom prior preventive treatments had failed (TF) (≥1, ≥2, and ≥3 TF medication categories) and never failed (preventive
Autor:
Uwe Reuter, David W. Dodick, Gregor Broessner, Jan Klatt, Feng Zhang, Jo H. Bonner, Hernan Picard, Robert A. Lenz, Daniel D. Mikol, Yngve Hallstrom
Publikováno v:
Headache
OBJECTIVE To assess the efficacy of erenumab at the ≥50%, ≥75%, and 100% reduction in monthly migraine days (MMD) response thresholds, using data from the 6-month double-blind treatment phase (DBTP) of the Study to Evaluate the Efficacy and Safet
Autor:
Ian K. Wright, Gregor Broessner, Uwe Reuter, Robert A. Lenz, Daniel D. Mikol, Yngve Hallström, Feng Zhang, Jo H. Bonner, Hernan Picard, Jan Klatt, Peter J. Goadsby, Denise E. Chou
Publikováno v:
Neurology
article-version (Version of Record) 3
article-version (Version of Record) 3
ObjectiveTo assess efficacy and tolerability of 1-year erenumab treatment in patients with episodic migraine.MethodsPatients were randomized (n = 955; 1:1:1) during the 24-week double-blind treatment phase (DBTP) to monthly subcutaneous placebo or er
Autor:
Osa Eisele, Uwe Reuter, Frank Hong, Julie Wang, Feng Zhang, David W. Dodick, Sunfa Cheng, David Kudrow, Julio Pascual, Jonathan N. Latham, Daniel D. Mikol, Hernan Picard, Paul Winner, Stewart J. Tepper, Jan Klatt
Publikováno v:
Neurology
ObjectiveTo examine the cardiovascular, cerebrovascular, and peripheral vascular safety of erenumab across migraine prevention studies.MethodsVascular adverse events (AEs) and blood pressure data were integrated across 4 double-blind, placebo-control